Nalin Ug, DO
Allergy & Immunology · Edmond, OKNPI 1285016493
Payments from drug & device makers
Across 618 payments — averaging $151.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$84K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$1K
- Grifols USA, LLC$968
- Takeda Pharmaceuticals U.S.A., Inc.$939
- plus $4K from 30 others
Across 7 payments — averaging $212.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1K
What the payments were for
- Speaking & faculty fees$78,31584%
- Travel & lodging$1,5872%
- Food & beverage$13,22114%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 162 | $83,732 |
| Sanofi | 44 | $1,161 |
| Regeneron Healthcare Solutions, Inc. | 49 | $1,024 |
| GSK | 63 | $1,011 |
| Grifols USA, LLC | 43 | $968 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $939 |
| CSL Behring | 34 | $837 |
| Genentech USA, Inc. | 17 | $342 |
| Alk-abello, Inc | 9 | $336 |
| Sanofi-aventis U.S. LLC | 9 | $326 |
| Pharming Healthcare, Inc. | 11 | $257 |
| Kaleo, Inc. | 13 | $254 |
| Amgen | 14 | $241 |
| Optinose US, Inc. | 7 | $202 |
| Octapharma USA, Inc. | 6 | $176 |
| Biocryst US Sales Co., LLC | 7 | $173 |
| Novartis | 7 | $157 |
| Upsher-smith Laboratories LLC | 8 | $146 |
| Teva Pharmaceuticals USA, Inc. | 10 | $143 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $142 |
| AbbVie | 24 | $128 |
| Pfizer | 7 | $118 |
| Biohaven Pharmaceuticals, Inc. | 6 | $98 |
| Blueprint Medicines Corporation | 5 | $94 |
| Greer Laboratories, Inc. | 2 | $60 |
| Ionis Pharmaceuticals, Inc. | 2 | $47 |
| Organon | 3 | $37 |
| Aimmune Therapeutics, Inc. | 2 | $37 |
| GC Biopharma USA, Inc. | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Biocryst Pharmaceuticals, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| ADMA Biomanufacturing LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$81,142
- BREZTRI$517
- TEZSPIRE$336
- FASENRA$282
- BEVESPI AEROSPHERE$169
- FARXIGA$169
- Xembify$165
- NUCALA$125
- DUPIXENT$119
- BREZTRI AEROSPHERE$110
How this compares
Too few allergy & immunology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $134,749 |
| XolairOmalizumab | 16 | $81,895 |
| XembifyImmune Globulin,gamma(Igg)klhw | 17 | $79,092 |
| Cromolyn Sodium | 31 | $12,385 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,927 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,730 |
| Epinephrine | 19 | $4,529 |
| Ipratropium Bromide | 41 | $1,045 |
| Gabapentin | 31 | $243 |
| Azithromycin | 17 | $227 |
| Famotidine | 28 | $206 |
| Montelukast Sodium | 17 | $67 |
| Prednisone | 18 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $939 | $134,74922 claims |
| Grifols USA, LLCXembify | $968 | $79,09217 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $19 | $12,38531 claims |
| GSKTrelegy Ellipta | $1,011 | $9,92714 claims |
| AstraZenecaBreztri Aerosphere | $83,732 | $6,73011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Edmond
- Iftikhar HussainTulsa$7.1M
- Amy DarterOklahoma City$559K
- Bret HaymoreBroken Arrow$368K
- Shahan StutesOklahoma City$43K
- Weyman LamTulsa$30K
- Lynn WiensTulsa$20K
- Terence CareyTulsa$16K
- Timothy TrojanEnid$13K
- Dean AtkinsonOklahoma City$13K
- Laura ChongOklahoma City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.